Understanding how poxviruses produce proteins after replication

Mechanisms regulating poxvirus post-replicative protein synthesis

NIH-funded research Texas A&m Agrilife Research · NIH-10666342

This study is looking at how a virus called vaccinia helps make proteins after it copies its DNA, and it could lead to new ways to improve vaccines and cancer treatments that might help patients in the future.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionTexas A&m Agrilife Research NIH-funded
Lab location1 site (College Station, UNITED STATES)
Project IDNIH-10666342 on NIH RePORTER

What this research studies

This research investigates the mechanisms by which poxviruses, particularly the vaccinia virus, regulate the synthesis of proteins after their DNA has replicated. The focus is on understanding how a specific feature of the viral mRNA, known as a 5'-poly(A) leader, enhances the translation of these proteins. By studying the interactions between viral and cellular factors during this process, the research aims to uncover fundamental insights that could lead to new applications in vaccines and cancer treatments. Patients may benefit from advancements in therapies that utilize poxviruses as anti-cancer agents.

Who could benefit from this research

Good fit: Ideal candidates for participation or benefit would include individuals with cancers that may be treated with poxvirus-based therapies.

Not a fit: Patients with non-cancerous conditions or those not eligible for poxvirus-based treatments may not receive any benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved poxvirus-based therapies for cancer treatment.

How similar studies have performed: Other research has shown promise in using poxviruses as therapeutic agents, indicating that this approach has potential for success.

Where this research is happening

College Station, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer AgentsCancer DrugNeoplastic Disease Chemotherapeutic Agentsanti-cancer druganticancer agent
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.